SCHEMBL17356909

SCHEMBL17356909

O=C(NO)C1=C(O)CCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 0.42
HDAC8 Q9BY41 5/20 0.42
HDAC2 Q92769 3/20 0.42
HDAC4 P56524 2/20 0.42
HDAC1 Q13547 4/20 0.39
HDAC3 O15379 2/20 0.39
HDAC7 Q8WUI4 2/20 0.39
HDAC5 Q9UQL6 1/20 0.39
GABRR1 P24046 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MPO P05164 1/20 0.31
GAA P10253 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HIF1A Q16665 1/20 0.31
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
IDO1 P14902 1/20 0.30
ALOX15 P16050 1/20 0.30
CA9 Q16790 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5517274 0.79 ALDH1A1 (0.37) KDM4EMPOGAASMN1; SMN2HIF1A
SCHEMBL14439039 0.77 ALDH1A1 (0.40) KDM4EMPOGAASMN1; SMN2HIF1A
SCHEMBL1875182 0.76 DHODH (0.44) HDAC6HDAC8HDAC2HDAC4HDAC1
SCHEMBL17356908 0.74 HDAC6 (0.41) HDAC6HDAC8HDAC2HDAC4HDAC1
SCHEMBL8321167 0.74 HDAC8 (0.41) HDAC6HDAC8HDAC2HDAC4HDAC1
SCHEMBL29008433 0.74
SCHEMBL1165189 0.72 HCAR2 (0.33) KDM4EGAASLC6A3
SCHEMBL13933872 0.71 SLC6A3 (0.49) SLC6A3
SCHEMBL9562844 0.70 DHODH (0.55) HDAC6HDAC8HDAC2KDM4EGAA
SCHEMBL12168628 0.70 SLC6A3 (0.31) SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793538-B2 Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors THE BROAD INSTITUTE, INC. (US) 2020-10-06 US disclosed
US-20180215726-A1 CYCLOALKENYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS THE BROAD INSTITUTE, INC. (US) 2018-08-02 US disclosed
US-20180215726-A1 CYCLOALKENYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS THE BROAD INSTITUTE, INC. (US) 2018-08-02 US disclosed
US-9914717-B2 Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors THE BROAD INSTITUTE, INC. (US) 2018-03-13 US disclosed
US-9914717-B2 Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors THE BROAD INSTITUTE, INC. (US) 2018-03-13 US disclosed
US-20150368221-A1 CYCLOALKENYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS THE BROAD INSTITUTE, INC. 2015-12-24 US disclosed
US-20150368221-A1 CYCLOALKENYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS THE BROAD INSTITUTE, INC. 2015-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215726-A1 CYCLOALKENYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC3, HDAC7 HDAC6 9/4885HDAC8 8/4885HDAC2 7/4885
US-20150368221-A1 CYCLOALKENYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC3, HDAC7 HDAC6 10/4885HDAC8 9/4885HDAC2 7/4885
US-10793538-B2 Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors HDAC1, HDAC3, HDAC7 HDAC6 9/4885HDAC8 8/4885HDAC2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.